Application of tranilast in preparation of medicament for treating tuberculosis

Abstract

The invention discloses application of tranilast-combined anti-tuberculosis medicaments in preparation of a medicament for treating tuberculosis, and at least two of the tranilast-combined anti-tuberculosis medicaments (isonicotinyl hydrazine, rifampicin, pyrazinoic acid amide and ethambutol) are adopted. After the medicament combination is applied for 50 days, a patient can feel that skin damage is obviously alleviated; after the medicament combination is applied for 3 to 4 months, skin damage of the patient almost completely disappears with a speed obviously greater than that of a control group of pure anti-tuberculosis treatment, so that the anti-tuberculosis treatment course is greatly shortened, tissue damage such as atrophic scar formation and pigmentation can be reduced, and no obvious adverse reaction exists, which indicates that the tranilast-combined classical anti-tuberculosis medicaments have a synergistic anti-tuberculosis effect, are capable of obviously shortening the anti-tuberculosis treatment course and enhancing the anti-tuberculosis curative effect when used for resisting the tuberculosis, are good in toleration and relatively high in compliance of patients, free from obvious adverse reaction, and relatively good in clinical curative effect and security, and are expected to become necessary medicaments for combined treatment of the tuberculosis.

Description

technical field [0001] The invention belongs to the field of medicine, and particularly relates to the application of tranilast in the preparation of medicines for treating tuberculosis and the pharmaceutical composition containing tranilast. Background technique [0002] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis-complex (MTB-C) bacteria, which currently includes the following species: Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium microti and African Mycobacterium. According to the World Health Organization (WHO), there are 8,000,000 new cases of tuberculosis and 3,000,000 deaths each year, and 2,000,000,000 people are thought to be infected worldwide. Tuberculosis is the second leading killer of adults after HIV. Nearly 500,000 new cases of multidrug-resistant (MDR) TB occur each year, and the recent emergence of extensively drug-resistant (XDR-TB) TB heralds an epidemic of untreatable TB disease. New drugs with po...

AI Technical Summary

Problems solved by technology

[0004] Although these combinations together provide treatment for susceptible M. tuberculosis infection over a 4-6 month period, clinically resistant patients to this combination therapy occasionally occur. Treatment may lead to many adverse reactions, and long-term treatment compliance is generally poor, poor compliance can lead to treatment failure, resulting in drug resistance

Images